Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly and Apollo Group partner to raise awareness and improve healthcare solutions for obesity and type 2 diabetes in ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...